ECN

L'evento è stato accreditato dal Provider PLS Educational (3516-171808Ed. 1) per la professione del Medico Chirurgo nelle discipline di Gastroenterologia, Chirurgia Generale, Medicina Interna, Pediatria, Pediatria di Libera Scelta. L'evento prevede l'assegnazione di 10 crediti formativi.

SCIENTIFIC SECRETARIAT

Ambrogio Orlando Claudio Romano

FACULTY

Marina Aloi (Rome, Italy)

Alessandro Armuzzi (Rome, Italy)

Livia Biancone (Rome, Italy)

Calogero Cammà (Palermo, Italy)

Maria Cappello (Palermo, Italy)

Fabiana Castiglione (Naples, Italy)

Michele Citrano (Palermo, Italy)

Mario Cottone (Palermo, Italy)

Antonio Craxì (Palermo, Italy)

Valeria Criscuoli (Palermo, Italy)
Walter Fries (Messina, Italy)

Paolo Gionchetti (Bologna, Italy)

David Laharie (Bordeaux, France)

Paolo Lionetti (Florence, Italy)

Fabio Salvatore Macaluso (Trapani, Italy)

Salvatore Madonia (Palermo, Italy)

Erasmo Miele (Naples, Italy)
Filippo Mocciaro (Palermo, Italy)

Giuseppe Navarra (Messina, Italy)

Ambrogio Orlando (Palermo, Italy)

Emanuele Orlando (Palermo, Italy)

Claudio Papi (Rome, Italy)

Gilberto Poggioli (Bologna, Italy)


Sara Renna (Palermo, Italy)

Claudio Romano (Messina, Italy)
Chiara Sapienza (Catania, Italy)

Gaspare Solina (Palermo, Italy)

Maurizio Vecchi (Milan, Italy)

Francesco Vitale (Palermo, Italy)



SEDE

Grand Hotel Piazza Borsa Via dei Cartari, 18 - 90133 Palermo

SEGRETERIA ORGANIZZATIVA



PLS Educational Srl

Via della Mattonaia, 17 - 50121 Firenze Tel. 055 2462241 - Fax 055 2462270 E-mail: lisa.peruzzi@promoleader.com www.promoleader.com

THANKS TO ALL THE SPONSORS
FOR THEIR EDUCATIONAL
AND NO-CONDITIONING CONTRIBUTION
FOR THE CONGRESS REALIZATION






















Bovveldisease

Grand Hotel Piazza Borsa **Palermo** 9-10 dicembre 2016



Safety of immunosuppressive treatment in the management of Inflammatory

Boweldisease

Palermo, 9-10 dicembre 2016 This is the second edition of the congress held in December 2014 on the safety of the immunosuppressive

and biologics treatment in Inflammatory Bowel Disease (IBD). In this edition the focus will also be given within pediatric and surgery fields.

Infections and malignancies are the major issues for clinicians in the management of patients with IBD In this edition the focus will also be given within pediatric and surgery fields. Infections and malignancies are the major issues for clinicians in the management of patients with IBD because of concerns about the safety of drugs currently used in treatment, including immunosuppressive agents and tumor necrosis factor (TNF) antagonists. Infections are strongly associated with IBD both in their etiopathogenesis and in their clinical course. A number of viral infections, tuberculosis and other their etiopathogenesis and in their clinical course. A number of viral infections of intestinal disease with therapy-related infections create challenges for the successful management of intestinal disease with immunosuppressive agents or TNE antagonists.

therapy-related infections create challenges for the successful management of intestinal disease with immunosuppressive agents or TNF antagonists.

Recently published guidelines offer a strong support to deal with these issues.

Major concern about IBD patients with malignancies is related to the risk of maintaining immunosuppressant or anti-TNF therapy also after the diagnosis of malignancy and the management of immunosuppressant or anti-TNF therapy also after the diagnosis of malignancy. Further research is required to a clinical relapse of IBD in patients with a recent diagnosis of malignancy. Further research is required to optimize strategies for IBD patients with malignancies. At the moment, all therapeutic choice is made optimize strategies for IBD patients with malignancies. At the moment, all the sessions will be on an individual basis, with an integrative multidisciplinary approach.

The congress will develop the best strategies for managing these issues and all the sessions will be

on an individual basis, with an integrative mutionsciplinary approach.

The congress will develop the best strategies for managing these issues and all the sessions will be

Preceded by a cumicar case conferent with the topics.

Finally, will present the results of the network on the treatment with biologics of the IBD in Sicily and preceded by a clinical case coherent with the topics. the final results of AIFA project on the safety of immunosuppressive treatment in IBD in our center.

Venerdì

9 dicembre 2016

14.15-14.30 Greetings from the General Manager of "VILLA SOFIA-CERVELLO" Hospital

Ina. G. Venuti

14.30-14.35 Introduction

M. Cottone A. Orlando C. Romano

SESSION I

Chairmen: M. Cottone. A. Orlando

14.35-15.00 Network on biologics in Sicily, advantages and limitations:

up to date M. Cottone

15.00-15.15 Discussion

15.15-15.40 AIFA project on the safety

of immunosuppressive treatment: final results

A. Orlando

15.40-16.00 Discussion

SESSION II

Chairman: A. Craxi

16.00-16.15 Clinical case C. Sapienza

16.15-16.40 Hepatitis B and C virus infection and

Immunosuppressive therapy in patients with IBD in children and adults

S. Madonia

16.40-17.05 Is it CMV infection

a contraindication to immunosuppressive and biological therapy in children

and adults? V. Criscuoli

17.05-17.30 Immunosuppressive

(thiopurines, methotrexate...) treatment related infections

in adults W. Fries

Immunosuppressive 17.30-17.55

(thiopurines, methotrexate...) treatment related infections

in children C. Romano

17.55-18.20 Biological treatment related infections in children and

> adults S. Renna

18.20-18.45 Discussion

SESSION III

Chairmen: E. Miele, M. Vecchi

Sabato

08.30-08.45 Clinical case E. Orlando

08.45-09.10 Risk of Cancer in IBD

patients treated with biologics

10 dicembre 2016

L. Biancone

09.10-09.40 Risk of Cancer in

IBD patients treated with thiopurines and methotrexate and management in patients with Cancer history:

updating D. Laharie

09.40-10.10 Which is the safety profile

of new biological drugs? F. Mocciaro

10.10-10.45 Discussion

10.45-11.00 COFFEE BREAK

SESSION IV

Chairmen: M. Cappello, P. Lionetti

11.00-11.15 Clinical case

M. Citrano

Biologics in early onset 11.15-11.40 Inflammatory Bowel

Disease: indications and treatment related safety M. Aloi

11.40-12.05 Biologics in elderly: indications and treatment

related safety M. Cottone

12.05-12.20 Discussion

12.20-12.45 Immunosuppressive

therapy in pregnancy and lactation in IBD patients

F. Castialione

12.45-13.10 Role of vaccines in

patients treated with immunosuppressants and

biologics: updating

F. Vitale

13.10 - 13.30 Paradoxical reactions to biologics in patients

with IBD A. Armuzzi

13.30-13.50 Discussion

13.50-15.00 LUNCH

SESSION V

Chairmen: C. Cammà, G. Navarra

15.00-15.15 Clinical Case F.S. Macaluso

15.15-15.45 Tandem Talk: Biological

treatment increases infectious complications related to surgery in

Ulcerative Colitis? P. Gionchetti, G. Poggioli

15.45-16.05 Discussion

16.05-16.35 Tandem Talk: Biological

treatment increases infectious complications related to surgery in Crohn's

Disease?

C. Papi, G. Solina

16.35-16.50 Discussion

16.50-17.00 Closing remarks A. Orlando, C. Romano

17.00-17.20 CME completion